Project Grant R01NS144085
- The National Institute of Neurological Disorders and Stroke awarded Northwestern University $566,529 on April 24, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate age-related deficits in trophic support of dopamine neurons in preclinical models of Parkinson's disease. The research examines cell-type-specific alterations in LRRK2G2019S mice to determine how the LRRK2 mutation affects neuroprotective signaling...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $540,901 on April 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate molecular mechanisms underlying dopamine signaling dysfunction in advanced Parkinson's disease. The research examines how striatal projection neurons become maladaptive during disease progression and why L-DOPA therapy loses efficacy over time. The work focuses...
- The National Institute of Neurological Disorders and Stroke awarded The University of Iowa $540,503 on May 7, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct basic neuroscience research on cerebellar interactions with forebrain structures during associative learning. The research systematically analyzes how the cerebellum interacts with the anterior cingulate cortex and hippocampus during trace conditioning in rats....
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $671,445 to Weill Medical College of Cornell University on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds development of an integrated pipeline for early Parkinson's disease prediction and disease-modifying drug repurposing. The work targets the...
- The National Institute of Neurological Disorders and Stroke awarded The Regents of the University of California, San Francisco $595,208 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Assistance Listing Project Grant R01NS148534). The award funds research investigating striatal synaptic plasticity mechanisms underlying cognitive dysfunction in Parkinson's disease. The project examines circuit- and synaptic-level...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, awarded The University of Iowa $582,252 on February 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop and validate predictive tools for cognitive outcomes following ischemic stroke. The research program develops methods to generate personalized, quantitative predictions of long-term stroke-related...
- The National Institute of Neurological Disorders and Stroke awarded the University of Georgia Research Foundation $1,297,188 on May 8, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate neuroinflammatory epitranscriptomic mechanisms in Parkinson's disease. The research examines the role of the ALKBH5 demethylase enzyme in microglial neuroinflammatory responses triggered by alpha-synuclein aggregates, a hallmark...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded Midwestern University $553,721 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to evaluate the efficacy and mechanisms of a novel manganese porphyrin compound in a Drosophila model of Parkinson's disease. The research measures brain levels of oxidized and...
- The National Institute of Neurological Disorders and Stroke awarded Purdue University $583,633 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate region-specific effects of pathology and vocal training on vocalization in a preclinical mouse model of Parkinson's disease. The research addresses voice and communication deficits that occur early in Parkinson's disease and significantly impact quality of life,...
- The National Institute of Neurological Disorders and Stroke awarded Rutgers, The State University of New Jersey $677,059 on July 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of tonic dopamine release in Parkinson's disease motor deficits. The research uses a genetic mouse model lacking synaptojanin1 (SYNJ1) in dopamine neurons to define the molecular basis and network consequences of dopamine...
The National Institute of Neurological Disorders and Stroke awarded The University of Iowa $597,466 on September 2, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate dopamine circuitry underlying executive dysfunction in Parkinson's disease. The research maps how dorsomedial striatal dopamine engages medium-spiny neuron ramping activity during interval timing, an elementary executive process impaired in patients with Parkinson's disease dementia. The project combines dopamine fiber photometry, optogenetics, neuronal recording, and computational modeling in mouse models to explore fundamental striatal circuit mechanisms. Current treatments for Parkinson's motor symptoms do not improve and can worsen executive function, creating a critical need for new neurophysiological markers and targeted interventions. Work is performed in Iowa City, Iowa. The award runs through May 31, 2031, as a Project Grant (R01NS144085) classified as basic research to reduce the burden of neurological disease. The research addresses a long-term goal of mapping circuits underlying executive functions in Parkinson's disease to inform development of new treatments for cognitive symptoms including working memory, attention, and timing deficits that contribute to dementia, employment loss, nursing home placement, and mortality.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $597.5k | 9/2/26 |